Last $0.22 USD
Change Today -0.0198 / -8.38%
Volume 40.4K
RGRX On Other Exchanges
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

regenerx biopharmaceuticals (RGRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/14 - $0.28
52 Week Low
12/30/13 - $0.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

regenerx biopharmaceuticals (RGRX) Related Businessweek News

No Related Businessweek News Found

regenerx biopharmaceuticals (RGRX) Details

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of molecules for tissue and organ repair. The company develops its product candidates based on Thymosin beta 4 (Tß4), an amino acid peptide. Its products include RGN-259, a topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology that has completed the Phase IIa exploratory clinical trial; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications treated by systemic administration that has completed Phase I clinical trial; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue that is in Phase II clinical trial. The company also seeks to identify and evaluate Tß4 peptide fragments and derivatives used as components in cosmeceutical and consumer products. RegeneRx Biopharmaceuticals, Inc. has a strategic partnership with Defiante Farmaceutica S.A. for the development and marketing of RGN-137 and RGN-352 for specified indications in Europe and other countries; and a license agreement with Lee's Pharmaceutical (HK) Limited for the license of Tß4 in various pharmaceutical forms. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was founded in 1982 and is headquartered in Rockville, Maryland.

5 Employees
Last Reported Date: 04/4/14
Founded in 1982

regenerx biopharmaceuticals (RGRX) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $62.5K
Founder, Chairman, Chief Scientific Advisor a...
Total Annual Compensation: $32.7K
Vice President of Clinical & Regulatory Affai...
Total Annual Compensation: $97.2K
Compensation as of Fiscal Year 2012.

regenerx biopharmaceuticals (RGRX) Key Developments

Regenerx Biopharmaceuticals Inc. announced delayed annual 10-K filing

On 04/01/2014, Regenerx Biopharmaceuticals Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

RegeneRx Biopharmaceuticals Wins USD 1.35 Million Under Product License and Securities Purchase Agreement

RegeneRx Biopharmaceuticals announced the receipt of the initial USD 1.35 million payment pursuant to its product license and securities purchase agreement with G-treeBNT Co. Under the agreement, G-treeBNT will develop RegeneRx's RGN-259 preservative-free eye drop product candidate in Asia (excluding China, Hong Kong, Taiwan and Macau). In addition, G-treeBNT will develop RegeneRx's RGN-137 topical dermal gel product candidate in the US. As part of the agreement, G-treeBNT purchased stock at USD 0.12 per share, will make an additional equity investment of USD 1.0 million at USD 0.12 per share by August 31, 2014 as well as retain an option until January 31, 2015 to purchase additional common stock for USD 825,000 at USD 0.15 per share.

RegeneRx and Digital Aria Sign Product License Agreement

RegeneRx Biopharmaceuticals Inc. announced that it has entered into two product license agreements with Digital Aria Co. Ltd. to develop RegeneRx's RGN-259 preservative-free eye drop product candidate in Asia (excluding China, Hong Kong, Taiwan, and Macau), and its RGN-137 topical dermal gel product candidate in the U.S. Digital Aria will also make an equity investment into RegeneRx of $2.35 million enabling RegeneRx to move forward with its ophthalmic clinical program, and retains a 10-month option to purchase additional common stock for $825,000. Digital Aria previously paid $150,000 to RegeneRx pursuant to a term sheet signed in February. License terms include commercial milestone payments of up to $7 million and a double digit royalty on commercial sales, if any. Digital Aria will be required to initiate Phase 2 clinical trials in the U.S. and Australia within three years. RegeneRx will receive a royalty-free license outside of the licensed territories to any improvements made by Digital Aria to RegeneRx's product candidates. The license will be exclusive in the U.S. with respect to RGN-137. With respect to RGN-259, it will be exclusive in Korea, Japan, Australia, New Zealand, Brunei, Cambodia, East Timor, Indonesia, Laos, Malaysia, Mongolia, Myanmar (Burma), Philippines, Singapore, Thailand, Vietnam, and Kazakhstan, and semi-exclusive in India, Pakistan, Bangladesh, Bhutan, Maldives, Nepal, Sri Lanka, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan. Digital Aria will pay for all costs associated with the development of any potential product within the licensed territories. RegeneRx retains the manufacturing and supply rights for T4 (the active pharmaceutical ingredient in the licensed product candidates) in the licensed territories.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGRX:US $0.22 USD -0.0198

RGRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RGRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation RGRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 600.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 667.7x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERX BIOPHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at